Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
Respiratory Care|December 2, 2004
Lung adenocarcinoma presenting with enlarged and multiloculated cystic lesions over 2 yearsTakayuki Yoshida, Toshiyuki Harada, Satoshi Fuke, et al.
International Journal of Radiation Oncology, Biology, Physics|August 20, 2005
Insertion and fixation of fiducial markers for setup and tracking of lung tumors in radiotherapyMikado Imura, Koichi Yamazaki, Hiroki Shirato, et al.
Bioorganic & Medicinal Chemistry|September 26, 2015
Identification and in silico prediction of metabolites of the model compound, tebufenozide by human CYP3A4 and CYP2C19Naoki Shirotani, Moe Togawa, Shinichi Ikushiro, et al.
Journal of Neurophysiology|November 19, 2005
Involvement of dorsal column nucleus neurons in nociceptive transmission in aged ratsJunichi Kitagawa, Yoshiyuki Tsuboi, Akiko Ogawa, et al.
Oncology Letters|July 10, 2023
A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202Minehiko Inomata, Yosuke Kawashima, Ryota Saito, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2019
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203Yoko Tsukita, Akira Inoue, Shunichi Sugawara, et al.
The Oncologist|May 21, 2017
Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301Eisaku Miyauchi, Akira Inoue, Kazuhiro Usui, et al.
International Journal of Clinical Oncology|November 13, 2020
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302Yosuke Kawashima, Toshiyuki Harada, Yuka Fujita, et al.
Cancer Diagnosis & Prognosis|July 4, 2024
Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive <i>EGFR</i>-mutant Non-small Cell CarcinomaMinehiko Inomata, Yosuke Kawashima, Ryota Saito, et al.
International Journal of Radiation Oncology, Biology, Physics|April 16, 2003
Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapyHiroki Shirato, Toshiyuki Harada, Tooru Harabayashi, et al.
Pageof 12